Publication date: Nov 29, 2024
Our previous study of 291 cancer patients, we showed that 20% did not respond to two doses of COVID-19 vaccine administered six weeks apart. Here, we investigated if psychological factors (distress, anxiety, and depressive symptoms) affected antibody response and markers of vaccine activation (D-dimer) after 6 months from initial vaccination. Overall, 31 subjects (14. 2%) had no antibody response at 6 months. Our analysis revealed significant predictors of vaccine failure, including the stage of metastatic disease and high-stress levels (OR = 2. 46, 95% CI, 1. 05-5. 77, p = 0. 04). Notably, nonresponders showed twice the prevalence of distress than responders (21% vs. 10%, p = 0. 04). Longitudinal measurements of IgG levels indicated that participants with high depressive symptoms at baseline maintained lower antibody levels over six months (p = 0. 003). In addition, women with high anxiety showed reduced levels of D-dimer at 6 months (p = 0. 03). These data also showed that smokers and former smokers had significantly lower antibody levels than their nonsmoking counterparts (p = 0. 0004). At baseline, the high discomfort rate (≥5) was 34. 4% in women and 23. 8% in men; only men experienced an increase in median discomfort during the observation period. Moreover, a higher educational level was related to increased distress among women (p = 0. 046). These findings underscore a critical association between elevated psychological distress and reduced immune responses to the COVID-19 vaccine, emphasizing the urgent need for targeted psychological and behavioral support within this vulnerable population.
Open Access PDF
Concepts | Keywords |
---|---|
Bnt162b2 | anxiety disorders |
Cancers | C reactive protein |
Months | COVID-19 vaccines |
Stage | D dimer |
Vaccination | depressive disorder |
immunogenicity | |
neoplasms | |
psychological distress | |
vaccine |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Anxiety |
disease | MESH | Depressive Symptoms |
disease | MESH | Cancer |
disease | MESH | educational level |
disease | MESH | psychological distress |
drug | DRUGBANK | Coenzyme M |
disease | MESH | COVID 19 |
disease | MESH | depressive disorder |
disease | MESH | anxiety disorders |
disease | IDO | protein |
disease | MESH | morbidity |
disease | IDO | production |
drug | DRUGBANK | Cysteamine |
disease | MESH | seroconversion |
disease | MESH | thrombocytopenia |
disease | MESH | thrombosis |
disease | MESH | lymphopenia |